FDA has also released Draft Guidance for Industry on Expedited Programs for Serious Conditions which includes a chart of the qualifying features, criteria, timelines for FDA action and other elements of the Fast Track, Breakthrough Therapy and Priority Review designations and Accelerated Approval pathway.